Clinical Research Of Paclitaxel Plus Oxaliplatin Versus Capecitabine Plus Oxaliplatin As First-line Treatment For Advanced Gastric Cancer

Objective: The aim of this study is to compare the efficacy and toxicity ofpaclitaxel plus oxaliplatin with capecitabine plus oxaliplatin as first-line trea-ment for advanced gastric cancer.Methods:69cases of advanced gastric cancer which were diagnosedand treated at Fujian Union Hospital from January2011and June2013wereretrospectively analized. Among them:36patients in experimental groupreceived paclitaxel combination with oxaliplatin program, and33patients incontrol group were treated with capecitabine plus oxaliplatin regimen.Evaluatethe efficacy and toxicity。Results:In experimental group and control group：RR were47.2%and42.4%, DCR were77.8%and72.7%, median PFS were5.3months and5.0months, and median OS were11.5months and10.7months. There was nosignificance between experimental group and control group(P>0.05).Inside-effect, the incidence of alopecia and grade III-IV neutropenia inexperimental group were higher than in control group.Yet, more patients incontrol group developed hand-foot syndrome and grade III-IV vomiting than inexperimental group. Other side effects were similar in the two groups, mainlyin leucopenia,neutropenia, nausea, vomiting and neurotoxicity, Most of theseside effects were of gradeⅠ-Ⅱ.Conclusions:In terms of efficacy, paclitaxel plus oxaliplatin andcapecitabine plus oxaliplatin are active therapeutic equivalence.For patientswith advanced gastric cancer, paclitaxel plus oxaliplatin is well tolerated.